749928-59-4

Upstream product

• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 124276-95-5 1-(3-bromophenyl)cyclopropane-1-carboxylic acid 
• 74-88-4 methyl iodide 
• 1878-67-7 3-Bromophenylacetic acid 
• 106-93-4 ethylene dibromide 

Downstream Products

• 886366-33-2 [1-(3-bromophenyl)cyclopropyl]methanol 
• 1346690-15-0 {[1-(3-bromophenyl)cyclopropyl]methoxy}(triisopropyl)silane 
• 1346690-16-1 3-(1-{[(triisopropylsilyl)oxy]methyl}cyclopropyl)benzaldehyde 
• 1346690-17-2 [3-(1-{[(triisopropylsilyl)oxy]methyl}cyclopropyl)phenyl]methanol 
• 1418296-16-8 (1-{3-[(3-{(Z)-1-fluoro-2-[4-(trifluoromethoxy)phenyl]vinyl}-5-methyl-1H-pyrazol-1-yl)methyl]-phenyl}cyclopropyl)methanol 
• 1418296-19-1 (1-{3-[(3-{(Z)-1-fluoro-2-[3-fluoro-4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl]vinyl}-5-methyl-1H-pyrazol-1-yl)methyl]phenyl}cyclopropyl)methanol 

Relevant academic research and scientific papers

Efficient cyclopropanation of aryl/heteroaryl acetates and acetonitriles with vinyl diphenyl sulfonium triflate

A convenient method was developed for the cyclopropanation of aryl acetates and aryl acetonitrile using vinyl diphenyl sulfonium triflate salt. The newly developed conditions are simple, mild, and compatible with a wide range of functional groups, without the need to apply an inert atmosphere, or alkali bases.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

MACROCYCLIC FACTOR VIIA INHIBITORS

The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS

The present application relates to novel substituted 5-(1,2,4-oxadiazol-5-yl)pyridin-2-ones and 6-(1,2,4-oxadiazol-5-yl)pyridazin-3-ones, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for producing medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures.

3-(Fluorovinyl)pyrazoles and their use

The present application relates to novel 3-(fluorovinyl)pyrazole derivatives, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.